138 filings
Page 3 of 7
POS AM
5kxv2ltv0mcae3p
1 May 23
Prospectus update (post-effective amendment)
5:19pm
S-8
81aeno4
1 May 23
Registration of securities for employees
5:15pm
6-K/A
ya58qit8zpct43wqf82s
1 May 23
Prenetics Announces Fourth Quarter and Full Year 2022 Financial Results
4:03pm
6-K
3wvd9 k2cqzh0g
14 Mar 23
Prenetics Announces Fourth Quarter and Full Year 2022 Financial Results
10:46am
6-K
095586rf0
2 Mar 23
Prenetics Announces Formation of Scientific Advisory Board to Support
7:39am
6-K
mzv3i8
19 Jan 23
Prenetics Announces Dr. Bayju Thakar as Chief Executive Officer of Prenetics EMEA
8:49am
424B3
v58j1 ddujdr2
17 Jan 23
Prospectus supplement
6:12am
6-K
plrkuzoq 1f
10 Jan 23
Current report (foreign)
7:48am
6-K
qv5 ep3er
16 Dec 22
Prenetics Acquires ACT Genomics, Creating a Leader in Comprehensive Cancer Genetics and Precision Oncology
8:06am
EFFECT
705z8ofwretorcjdy
15 Dec 22
Notice of effectiveness
12:15am
POS AM
hmdz 2eisnjn
14 Dec 22
Prospectus update (post-effective amendment)
8:04am
6-K
flp0 25y6skap8yp7s
30 Nov 22
Prenetics Announces US$20 Million Stock Repurchase Program and Inclusion into the MSCI Global Micro Cap Index
6:15am
6-K
4h35wii4
10 Nov 22
Prenetics Announces Record Third Quarter 2022 Financial Results and Raises Full Year 2022 Revenue and EBITDA Guidance
4:04pm
S-8
j17ssrcdu4vrd
19 Oct 22
Registration of securities for employees
9:20pm
6-K
opan hucun5
22 Sep 22
Current report (foreign)
6:06am
6-K
f90cq 0a72
9 Sep 22
Prenetics Announces Second Quarter 2022 Financial Results and Raises Full Year Adjusted EBITDA Outlook
4:32pm
424B3
g9ao 00zbk3
1 Jul 22
Prospectus supplement
4:10pm
EFFECT
8jkw3d71 8rexhu9l
1 Jul 22
Notice of effectiveness
12:15am
F-1/A
s16ny 8p60g5wgro
28 Jun 22
Registration statement (foreign) (amended)
4:02pm